Contact
searchSearch
HMP Global

Ankylosing Spondylitis Topic Center

Featured Article

News
Opioid Use Associated With Fractures in People With Ankylosing Spondylitis
12/20/2023
Lisa Kuhns, PhD, MD
Increasing age, historical fracture, and opioid use are associated with higher odds of fracture in ankylosing spondylitis (AS), according to a study published in Arthritis Care & Research. “We performed a retrospective cohort study...
Increasing age, historical fracture, and opioid use are associated with higher odds of fracture in ankylosing spondylitis (AS), according to a study published in Arthritis Care & Research. “We performed a retrospective cohort study...
Increasing age, historical...
12/20/2023
First Report Managed Care
News
Analysis Finds Similar Safety Profile with Upadacitinib Across Conditions
11/03/2023
Jolynn Tumolo
The Janus kinase (JAK) inhibitor upadacitinib offers a similar long-term safety profile across rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and atopic dermatitis (AD) despite some variations in adverse...
The Janus kinase (JAK) inhibitor upadacitinib offers a similar long-term safety profile across rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and atopic dermatitis (AD) despite some variations in adverse...
The Janus kinase (JAK) inhibitor...
11/03/2023
First Report Managed Care
News
High Rates of Depression, Anxiety in Patients With Ankylosing Spondylitis
10/06/2023
Jolynn Tumolo
Half of patients with ankylosing spondylitis had clinically significant depression, and more than a third had clinically significant anxiety, according to a single-center, cross-sectional study currently underway.
Half of patients with ankylosing spondylitis had clinically significant depression, and more than a third had clinically significant anxiety, according to a single-center, cross-sectional study currently underway.
Half of patients with ankylosing...
10/06/2023
First Report Managed Care
News
Achieving Disease Control in PsA, AS Associated with Lower Medical Costs
09/15/2023
Jolynn Tumolo
A study published in Rheumatology and Therapy found that individuals diagnosed with psoriatic arthritis (PsA) or ankylosing spondylitis (AS) and exhibiting lower levels of disease activity incurred reduced healthcare resource utilization and...
A study published in Rheumatology and Therapy found that individuals diagnosed with psoriatic arthritis (PsA) or ankylosing spondylitis (AS) and exhibiting lower levels of disease activity incurred reduced healthcare resource utilization and...
A study published in...
09/15/2023
First Report Managed Care
News
Can Tumor Necrosis Factor Inhibitors Reduce the Risk of Fractures in AS Patients?
08/30/2023
Danielle Sposato
Researchers sought to understand if fracture risk decreased among individuals with ankylosing spondylitis with tumor necrosis factor inhibitors treatments compared to non-AS patients.
Researchers sought to understand if fracture risk decreased among individuals with ankylosing spondylitis with tumor necrosis factor inhibitors treatments compared to non-AS patients.
Researchers sought to understand...
08/30/2023
First Report Managed Care
News
Fear of Movement in Patients With Ankylosing Spondylitis Linked With Lower Life Quality
07/27/2023
Jolynn Tumolo
Research findings indicate a link between kinesiophobia, a fear of movement and injury, and decreased quality of life in patients with ankylosing spondylitis.
Research findings indicate a link between kinesiophobia, a fear of movement and injury, and decreased quality of life in patients with ankylosing spondylitis.
Research findings indicate a...
07/27/2023
First Report Managed Care
News
Tildrakizumab No Better Than Placebo for Ankylosing Spondylitis
06/09/2023
Jolynn Tumolo
A 48-week trial of tildrakizumab in patients with ankylosing spondylitis was terminated early after researchers found that the drug had no efficacy in comparison to placebo.
A 48-week trial of tildrakizumab in patients with ankylosing spondylitis was terminated early after researchers found that the drug had no efficacy in comparison to placebo.
A 48-week trial of tildrakizumab...
06/09/2023
First Report Managed Care
News
Risk of Psychiatric Comorbidity Higher in Patients With Ankylosing Spondylitis
05/19/2023
Jolynn Tumolo
Findings from a population-based, cross-sectional study suggest that patients with ankylosing spondylitis are at a higher risk of developing psychiatric disorders.
Findings from a population-based, cross-sectional study suggest that patients with ankylosing spondylitis are at a higher risk of developing psychiatric disorders.
Findings from a...
05/19/2023
First Report Managed Care
News
Short-term Biosimilar Adalimumab Provides Long-term Relief for Ankylosing Spondylitis
04/14/2023
Jolynn Tumolo
Treatment with biosimilar adalimumab was associated with a significant improvement in ankylosing spondylitis symptoms for up to 1 year, according to new findings.
Treatment with biosimilar adalimumab was associated with a significant improvement in ankylosing spondylitis symptoms for up to 1 year, according to new findings.
Treatment with biosimilar...
04/14/2023
First Report Managed Care
News
JAK Inhibitor Improves Slate of Patient-Reported Outcomes in Biologic Refractory Ankylosing Spondylitis
03/28/2023
Jolynn Tumolo
Researchers studied a JAK inhibitor's efficacy for improving disease activity, health-related quality of life, and other measures in a cohort of patients with ankylosing spondylitis who did not respond or tolerate biologics.
Researchers studied a JAK inhibitor's efficacy for improving disease activity, health-related quality of life, and other measures in a cohort of patients with ankylosing spondylitis who did not respond or tolerate biologics.
Researchers studied a JAK...
03/28/2023
First Report Managed Care
News
Baseline Variables Predict Probability of Initial Response to TNFi Inhibitors in Patients With AS
10/27/2022
Edan Stanley
Researchers sought to develop models of the probability of short-term response to tumor necrosis factor inhibitor treatment in patients with ankylosing spondylitis.
Researchers sought to develop models of the probability of short-term response to tumor necrosis factor inhibitor treatment in patients with ankylosing spondylitis.
Researchers sought to develop...
10/27/2022
First Report Managed Care

Newsfeed

News
Opioid Use Associated With Fractures in People With Ankylosing Spondylitis
12/20/2023
Lisa Kuhns, PhD, MD
Increasing age, historical fracture, and opioid use are associated with higher odds of fracture in ankylosing spondylitis (AS), according to a study published in Arthritis Care & Research. “We performed a retrospective cohort study...
Increasing age, historical fracture, and opioid use are associated with higher odds of fracture in ankylosing spondylitis (AS), according to a study published in Arthritis Care & Research. “We performed a retrospective cohort study...
Increasing age, historical...
12/20/2023
First Report Managed Care
News
Analysis Finds Similar Safety Profile with Upadacitinib Across Conditions
11/03/2023
Jolynn Tumolo
The Janus kinase (JAK) inhibitor upadacitinib offers a similar long-term safety profile across rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and atopic dermatitis (AD) despite some variations in adverse...
The Janus kinase (JAK) inhibitor upadacitinib offers a similar long-term safety profile across rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and atopic dermatitis (AD) despite some variations in adverse...
The Janus kinase (JAK) inhibitor...
11/03/2023
First Report Managed Care
News
High Rates of Depression, Anxiety in Patients With Ankylosing Spondylitis
10/06/2023
Jolynn Tumolo
Half of patients with ankylosing spondylitis had clinically significant depression, and more than a third had clinically significant anxiety, according to a single-center, cross-sectional study currently underway.
Half of patients with ankylosing spondylitis had clinically significant depression, and more than a third had clinically significant anxiety, according to a single-center, cross-sectional study currently underway.
Half of patients with ankylosing...
10/06/2023
First Report Managed Care
News
Achieving Disease Control in PsA, AS Associated with Lower Medical Costs
09/15/2023
Jolynn Tumolo
A study published in Rheumatology and Therapy found that individuals diagnosed with psoriatic arthritis (PsA) or ankylosing spondylitis (AS) and exhibiting lower levels of disease activity incurred reduced healthcare resource utilization and...
A study published in Rheumatology and Therapy found that individuals diagnosed with psoriatic arthritis (PsA) or ankylosing spondylitis (AS) and exhibiting lower levels of disease activity incurred reduced healthcare resource utilization and...
A study published in...
09/15/2023
First Report Managed Care
News
Can Tumor Necrosis Factor Inhibitors Reduce the Risk of Fractures in AS Patients?
08/30/2023
Danielle Sposato
Researchers sought to understand if fracture risk decreased among individuals with ankylosing spondylitis with tumor necrosis factor inhibitors treatments compared to non-AS patients.
Researchers sought to understand if fracture risk decreased among individuals with ankylosing spondylitis with tumor necrosis factor inhibitors treatments compared to non-AS patients.
Researchers sought to understand...
08/30/2023
First Report Managed Care
News
Fear of Movement in Patients With Ankylosing Spondylitis Linked With Lower Life Quality
07/27/2023
Jolynn Tumolo
Research findings indicate a link between kinesiophobia, a fear of movement and injury, and decreased quality of life in patients with ankylosing spondylitis.
Research findings indicate a link between kinesiophobia, a fear of movement and injury, and decreased quality of life in patients with ankylosing spondylitis.
Research findings indicate a...
07/27/2023
First Report Managed Care
News
Tildrakizumab No Better Than Placebo for Ankylosing Spondylitis
06/09/2023
Jolynn Tumolo
A 48-week trial of tildrakizumab in patients with ankylosing spondylitis was terminated early after researchers found that the drug had no efficacy in comparison to placebo.
A 48-week trial of tildrakizumab in patients with ankylosing spondylitis was terminated early after researchers found that the drug had no efficacy in comparison to placebo.
A 48-week trial of tildrakizumab...
06/09/2023
First Report Managed Care
News
Risk of Psychiatric Comorbidity Higher in Patients With Ankylosing Spondylitis
05/19/2023
Jolynn Tumolo
Findings from a population-based, cross-sectional study suggest that patients with ankylosing spondylitis are at a higher risk of developing psychiatric disorders.
Findings from a population-based, cross-sectional study suggest that patients with ankylosing spondylitis are at a higher risk of developing psychiatric disorders.
Findings from a...
05/19/2023
First Report Managed Care
News
Short-term Biosimilar Adalimumab Provides Long-term Relief for Ankylosing Spondylitis
04/14/2023
Jolynn Tumolo
Treatment with biosimilar adalimumab was associated with a significant improvement in ankylosing spondylitis symptoms for up to 1 year, according to new findings.
Treatment with biosimilar adalimumab was associated with a significant improvement in ankylosing spondylitis symptoms for up to 1 year, according to new findings.
Treatment with biosimilar...
04/14/2023
First Report Managed Care
News
JAK Inhibitor Improves Slate of Patient-Reported Outcomes in Biologic Refractory Ankylosing Spondylitis
03/28/2023
Jolynn Tumolo
Researchers studied a JAK inhibitor's efficacy for improving disease activity, health-related quality of life, and other measures in a cohort of patients with ankylosing spondylitis who did not respond or tolerate biologics.
Researchers studied a JAK inhibitor's efficacy for improving disease activity, health-related quality of life, and other measures in a cohort of patients with ankylosing spondylitis who did not respond or tolerate biologics.
Researchers studied a JAK...
03/28/2023
First Report Managed Care
News
Outpatient Epcoritamab Dosing Feasible in R/R DLBCL, Study Finds
04/20/2026
Grace Taylor, MS, MA
According to a recent study, outpatient monitoring after epcoritamab initiation showed manageable safety and strong response rates in relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL), potentially reducing the need for routine...
According to a recent study, outpatient monitoring after epcoritamab initiation showed manageable safety and strong response rates in relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL), potentially reducing the need for routine...
According to a recent study,...
04/20/2026
First Report Managed Care
News
Location Creates Travel Burden and Treatment Inequities for Patients With DLBCL and FL
04/17/2026
Rebecca Amrick
A study observed inequities in the time and distance it takes patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) to travel for treatment.
A study observed inequities in the time and distance it takes patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) to travel for treatment.
A study observed inequities in...
04/17/2026
First Report Managed Care
News
Real-World Elranatamab in RRMM Falls Short on Durability Despite Strong Initial Responses
04/17/2026
Rebecca Amrick
Elranatamab shows promising response rates in real-world relapsed or refractory multiple myeloma (RRMM), but shorter durability, prior B-cell maturation antigen (BCMA) exposure, and high infection risk raise questions about optimal patient...
Elranatamab shows promising response rates in real-world relapsed or refractory multiple myeloma (RRMM), but shorter durability, prior B-cell maturation antigen (BCMA) exposure, and high infection risk raise questions about optimal patient...
Elranatamab shows promising...
04/17/2026
First Report Managed Care
News
Real-World Data Show Semaglutide’s Impact on Health Care Utilization and Medical Costs for Patients With OW/OB
04/17/2026
Rebecca Amrick
A large observational study of a US administrative claims database examined the effects of semaglutide on health care resource utilization (HCRU) and medical costs in patients with overweight or obesity (OW/OB) and multimorbidity.
A large observational study of a US administrative claims database examined the effects of semaglutide on health care resource utilization (HCRU) and medical costs in patients with overweight or obesity (OW/OB) and multimorbidity.
A large observational study of a...
04/17/2026
First Report Managed Care
News
Improving RVU Compensation Models to be More Equitable for Transplant Nephrologists
04/16/2026
Rebecca Amrick
A comprehensive study outlines the main issues with current compensation models for transplant nephrologists and provides solutions to improving these models.
A comprehensive study outlines the main issues with current compensation models for transplant nephrologists and provides solutions to improving these models.
A comprehensive study outlines...
04/16/2026
First Report Managed Care
News
Mail-Based FIT Program Increases CRC Screening in a Value-Based Care System
04/13/2026
Rebecca Amrick
A large, system-wide health initiative using mail-in fecal immunochemical tests (FIT) shows a slight increase in patient participation in colorectal cancer (CRC) screenings and prevention.
A large, system-wide health initiative using mail-in fecal immunochemical tests (FIT) shows a slight increase in patient participation in colorectal cancer (CRC) screenings and prevention.
A large, system-wide health...
04/13/2026
First Report Managed Care
News
What Real-World Data Reveal About R/R DLBCL Care
04/13/2026
Rebecca Amrick
A high variety of treatments options for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) has led to a lack of cohesion and disordered care for later lines of therapy.
A high variety of treatments options for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) has led to a lack of cohesion and disordered care for later lines of therapy.
A high variety of treatments...
04/13/2026
First Report Managed Care
News
Delays in Early-Stage NSCLC Surgery Linked to Systemic and Equity Gaps in Patients
04/13/2026
Rebecca Amrick
Systemic and equity gaps among patients with early-stage non–small cell lung cancer (NSCLC) lead to patients experiencing delayed surgical resection beyond the recommended 8-week window from diagnosis.
Systemic and equity gaps among patients with early-stage non–small cell lung cancer (NSCLC) lead to patients experiencing delayed surgical resection beyond the recommended 8-week window from diagnosis.
Systemic and equity gaps among...
04/13/2026
First Report Managed Care
News
Epcoritamab Plus R2 Maintains Quality of Life in R/R Follicular
04/10/2026
Hannah Musick
Epcoritamab plus rituximab and lenalidomide (R2) improved response rates in relapsed or refractory (R/R) follicular lymphoma while maintaining health-related quality of life despite higher rates of adverse events.
Epcoritamab plus rituximab and lenalidomide (R2) improved response rates in relapsed or refractory (R/R) follicular lymphoma while maintaining health-related quality of life despite higher rates of adverse events.
Epcoritamab plus rituximab and...
04/10/2026
First Report Managed Care
Behind the Bill
CMS Proposes FY 2027 Skilled Nursing Facility Payment and Quality Updates
04/10/2026
Grace Taylor, MS, MA
The Centers for Medicare & Medicaid Services (CMS) has proposed its rule for the Fiscal Year (FY) 2027 Skilled Nursing Facility Prospective Payment System (SNF PPS), which introduces a modest payment increase alongside key updates to quality...
The Centers for Medicare & Medicaid Services (CMS) has proposed its rule for the Fiscal Year (FY) 2027 Skilled Nursing Facility Prospective Payment System (SNF PPS), which introduces a modest payment increase alongside key updates to quality...
The Centers for Medicare &...
04/10/2026
First Report Managed Care

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use